PIM1 Antibody (Phospho-Tyr309) (OABF01229)

Catalog No: OABF01229

Size:100UL

Lane 1: mouse brain lysates Lane 2: human colon carcinoma lysates probed with Anti PIM1 (Tyr218) Polyclonal Antibody, Unconjugated (OABF01229) at 1:200 in 4C. Followed by conjugation to secondary antibody at 1:3000 90min in 37C. Predicted band 45kD. Observed band size: 45kD.

Product Info

• Tested Species Reactivity: Human, Mouse, Rat
• Predicted Species Reactivity: Bovine|Dog|Human|Mouse|Porcine|Rabbit|Rat|Sheep
• Product Format: Liquid Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.
• Clonality: Polyclonal
• Isotype: IgG
• Host: Rabbit
• Conjugation: Unconjugated
• Application: ELISA, ICC, IF, IHC-P
• Additional Information: Subcellular Location: Cytoplasm, Nucleus, Cell membrane
• Reconstitution and Storage: -20°C
• Immunogen: KLH conjugated synthetic phosphopeptide derived from human PIM1 around the phosphorylation site of Tyr218
• Purification: Protein A Purified
• Concentration: 1 ug/ul
• Target Post-Translational Modification: Tyr309
• Specificity: This phosphorylation site is also referred to as Tyr218, as this is the position in Isoform 2 of this protein. This phosphorylation site is homologous to Tyr302 in Mouse and Tyr218 in Rat.
• Application Info: WB: 1:300~1000
  ELISA: 1:500~1000
  IHC-P: 1:200~400
  IHC-F: 1:100~500
  Fluorescent (IHC-P): 1:50~200
  Fluorescent (IHC-F): 1:50~200
  Fluorescent-ICC: 1:50~200

Target Info

• Gene Symbol: PIM1
• Gene Full Name: Pim-1 proto-oncogene, serine/threonine kinase
• Alias Symbols: Oncogene PIM1;PIM;pim-1 oncogene (proviral integration site 1);proto-oncogene serine/threonine-protein kinase pim-1;serine/threonine-protein kinase pim-1.
• NCBI Gene Id: 5292
• Protein Name: Serine/threonine-protein kinase pim-1
• Description of Target: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.
• Uniprot ID: P11309